Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Galectin Therapeutics ( (GALT) ) just unveiled an announcement.
On March 5, 2025, Galectin Therapeutics announced the availability of its updated corporate presentation on its website, intended for use in investor and analyst meetings. The presentation highlights the company’s focus on advancing its clinical trials for Belapectin, which has shown promising results in reducing new varices in MASH cirrhosis patients and in cancer treatment when combined with checkpoint inhibitors. The company is also exploring potential partnerships and funding opportunities to support its ongoing research and development efforts.
More about Galectin Therapeutics
Galectin Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing therapies for chronic liver diseases and cancer. The company is known for its proprietary drug, Belapectin, a galectin-3 inhibitor aimed at treating MASH cirrhosis and portal hypertension, as well as being used in combination therapies for cancer treatment.
YTD Price Performance: 35.90%
Average Trading Volume: 768,987
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $99.07M
Learn more about GALT stock on TipRanks’ Stock Analysis page.